The new regulations of Guangdong drug trade point to the false high price of drugs and the approval of the industry

Source: 5 documents (hereinafter referred to as "trading rules") such as "drug trading rules of Guangdong Province (Trial) (Draft for comments)" were publicly solicited for comments on China news.com from June to May 17, 2013, which aroused strong response from pharmaceutical enterprises Many enterprises believe that many of the contents put forward in the document are very positive, but in general, they are contrary to many national policies Once implemented, it may lead to disorder of drug production and circulation, and expand the risk of drug quality Before that, five first-class industry associations in China have jointly written to the relevant government departments to put forward a large number of amendments to the new regulations, including many articles which have been strongly criticized and called for "fundamental amendments" On the afternoon of September 9, sponsored by e drug manager magazine, with the participation of China over the counter drug association, China Pharmaceutical Enterprise Management Association, China Association of traditional Chinese medicine, China Association for the promotion of scientific research and development of pharmaceutical industry and some members of the CPPCC National People's Congress of the pharmaceutical industry, on the drug trade rules of Guangdong Province (Trial) (Draft for comments) 》At the symposium, a number of representatives pointed out that the "transaction rules" proposed "transforming government functions and strengthening market mechanism", but set up a new administrative license to interfere with market behavior Among them, the "transaction rules" set the "market entry price" for enterprises to participate in drug transactions It is stipulated that the market entry price shall be determined by the leading group of centralized procurement work, and the online bidding price of enterprises shall not be higher than the "market entry price" This is considered as an act of restricting market access in the industry, which should be a newly established administrative license However, according to the transaction rules, medical institutions can only choose the dosage forms and specifications to be used in drug transactions, and can not directly choose the manufacturer, which is considered to limit the rights of medical institutions as the main procurement body Wu Yiling, a CPPCC member and chairman of Hebei Yiling Pharmaceutical Group Co., Ltd., believes that the trading rules set up an electronic trading platform to discover prices through the market mechanism, but also set up many restrictions on the way of price generation, including the setting and conditions of the market price, stipulating that in the process of enterprise bidding, the last offer is lower than the previous one, etc In addition, according to the transaction rules, the same product name of the same manufacturer can only be registered once The manufacturer must designate the distribution enterprise among the registered distribution enterprises The distribution enterprise must directly purchase, settle accounts and issue publications from the manufacturer Only one distribution enterprise can be selected for the same medical institution of a certain variety In principle, it is not allowed to change in the transaction process, and so on Degree of intervention in the main market behavior In terms of price mechanism, the new regulation is accused of "taking low price is taking", which may lead to a tragic drug "price war" Some representatives said that the new rules gave up the determination of the winning enterprises through comprehensive evaluation Although the comprehensive evaluation of economic and technical bid and commercial bid was adopted in the bidding of essential drugs, the economic and technical bid only accounted for 10% of the weight, and the price accounted for 90% Basically, the lowest bidder won the bid Xu Jingren, deputy to the National People's Congress and chairman of Yangzijiang Pharmaceutical Group, believes that some excellent enterprises have no cost-effective advantage with the lowest price as the bidding price The representative also pointed out that the transaction rules did not take into account the objective fact that there are different management levels and quality differences between the same kind of drugs in China's pharmaceutical enterprises Without quality evaluation, the transaction price is always the lowest price, which is not conducive to guiding enterprises to continuously improve the quality of drugs and ensure the safety of patients However, according to the report of China Times on June 7, quoting the president of a second-class hospital in Guangdong, the new regulations on drug trade in Guangdong are undoubtedly better than the existing plan, at least to some extent, it can curb the phenomenon of false high drug prices, and the operation space of "doctor's rebate" will be greatly compressed The reason for the strong opposition of pharmaceutical companies is that it challenges the "hidden rules" of the industry In addition, drug quality level division, bidding frequency, dosage form combination bidding, low-cost drug definition, etc are also the focus of the current query in the industry.